Starpharma (SPL.AX) Market Performance
Starpharma Holdings Limited shares fell 33.33 % during a 24‑hour period that ended at 09:43 PM Central Europe on Wednesday 21 October 2026. The stock is currently trading at approximately AUD 0.48 on major exchanges.
- Shares outstanding: 719.6 million.
- Market capitalisation: AUD 359.8 million.
- Volume traded in the last 24 hours: AUD 5.2 million.
- Last‑month performance: down 37.11 %.
- 200‑day simple moving average: AUD 0.63.
- 52‑week high: AUD 0.88 (30 September 2026).
- 52‑week low: AUD 0.30 (23 October 2025).
Transaction with Petalion Therapeutics
Starpharma Holdings Limited has increased its equity stake in Petalion Therapeutics from 22.5 % to 66 %, thereby acquiring majority ownership, governance control, and operational leadership of Petalion’s fibroblast activation protein‑targeted oncology programme. The transaction is partially funded with cash and research‑and‑development services.
Key implications of the deal include:
- Alignment of Petalion’s programme with Starpharma’s broader targeted‑oncology strategy.
- Direct control over the next development phase, including lead‑candidate selection and partnership planning.
- Retention of a 30 % interest and board representation by Medicxi, ensuring continued strategic and developmental expertise.
Starpharma will host an online briefing to explain the transaction and its impact on the company’s portfolio and capital allocation strategy.
Related Stock Movements (Last 24 Hours)
| Symbol | Trade % | Current Price (AUD) | Market Capitalisation (AUD) | Notes |
|---|---|---|---|---|
| Accent (AX1.AX) | –0.76 % | 0.66 | 396.8 million | – |
| Vysarn (VYS.AX) | –2.74 % | 0.71 | 430.5 million | P/E ratio 37.14 |
| Acorn Capital Investment Fund (ACQ) | – | – | – | AGM scheduled 19 Nov 2026; proposal for five‑year management agreement; FY 2026 dividend 7 cents/share |
| Santana Minerals (SMI.AX) | –2.35 % | 0.42 | 419 million | – |
| Beacon Lighting (BLX.AX) | +1.7 % | 1.76 | 403.6 million | P/E ratio 15.01; AGM 20 Oct 2026; strategic expansion plans |
| Artrya (AYA.AX) | –3.79 % | 2.65 | 430.2 million | Classified as downtrend; excess supply conditions noted |
About Starpharma Holdings Limited
Starpharma Holdings Limited is a biopharmaceutical company focused on the research and commercialization of dendrimer‑based products across health‑care and pharmaceutical sectors. The company prioritises unmet patient needs in oncology and infectious diseases. Further information is available on the company’s website at www.starpharma.com . The stock trades on the ASX All Markets.
